{"id":"https://openalex.org/W2604698186","doi":"https://doi.org/10.1016/j.bmcl.2017.04.004","title":"A calcineurin antifungal strategy with analogs of FK506","display_name":"A calcineurin antifungal strategy with analogs of FK506","publication_year":2017,"publication_date":"2017-04-03","ids":{"openalex":"https://openalex.org/W2604698186","doi":"https://doi.org/10.1016/j.bmcl.2017.04.004","mag":"2604698186","pmid":"https://pubmed.ncbi.nlm.nih.gov/28412204"},"language":"en","primary_location":{"id":"doi:10.1016/j.bmcl.2017.04.004","doi":"https://doi.org/10.1016/j.bmcl.2017.04.004","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.bmcl.2017.04.004","pdf_url":null,"source":{"id":"https://openalex.org/S30970080","display_name":"Bioorganic & Medicinal Chemistry Letters","issn_l":"0960-894X","issn":["0960-894X","1464-3405"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & Medicinal Chemistry Letters","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","pubmed"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5028653846","display_name":"Mitchell D. Nambu","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108517","display_name":"Amplyx Pharmaceuticals (United States)","ror":"https://ror.org/02jfsdq79","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108517"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Mitchell Nambu","raw_affiliation_strings":["Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States. Electronic address: mitch.nambu@yahoo.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States. Electronic address: mitch.nambu@yahoo.com","institution_ids":["https://openalex.org/I4210108517"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5074529368","display_name":"Jonathan A. Covel","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108517","display_name":"Amplyx Pharmaceuticals (United States)","ror":"https://ror.org/02jfsdq79","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108517"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jonathan A. Covel","raw_affiliation_strings":["Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States","institution_ids":["https://openalex.org/I4210108517"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068879729","display_name":"Mili Kapoor","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108517","display_name":"Amplyx Pharmaceuticals (United States)","ror":"https://ror.org/02jfsdq79","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108517"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mili Kapoor","raw_affiliation_strings":["Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States","institution_ids":["https://openalex.org/I4210108517"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5100452145","display_name":"Xiaoming Li","orcid":"https://orcid.org/0000-0003-1795-0371","observed_orcids":["https://orcid.org/0000-0003-1795-0371","https://orcid.org/0009-0005-9675-1144","https://orcid.org/0009-0008-6865-4867","https://orcid.org/0000-0002-0431-8564"]},"institutions":[{"id":"https://openalex.org/I4210108517","display_name":"Amplyx Pharmaceuticals (United States)","ror":"https://ror.org/02jfsdq79","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108517"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Xiaoming Li","raw_affiliation_strings":["Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States","institution_ids":["https://openalex.org/I4210108517"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014506220","display_name":"Molly K. Moloney","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108517","display_name":"Amplyx Pharmaceuticals (United States)","ror":"https://ror.org/02jfsdq79","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108517"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Molly K. Moloney","raw_affiliation_strings":["Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States","institution_ids":["https://openalex.org/I4210108517"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5065634267","display_name":"Mehdi M. D. Numa","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108517","display_name":"Amplyx Pharmaceuticals (United States)","ror":"https://ror.org/02jfsdq79","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108517"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Mehdi M. Numa","raw_affiliation_strings":["Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States","institution_ids":["https://openalex.org/I4210108517"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5087949227","display_name":"Quinlyn A. Soltow","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108517","display_name":"Amplyx Pharmaceuticals (United States)","ror":"https://ror.org/02jfsdq79","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108517"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Quinlyn A. Soltow","raw_affiliation_strings":["Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States","institution_ids":["https://openalex.org/I4210108517"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5027409273","display_name":"Michael Trzoss","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108517","display_name":"Amplyx Pharmaceuticals (United States)","ror":"https://ror.org/02jfsdq79","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108517"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Michael Trzoss","raw_affiliation_strings":["Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States","institution_ids":["https://openalex.org/I4210108517"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5015658574","display_name":"Peter J. Webb","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108517","display_name":"Amplyx Pharmaceuticals (United States)","ror":"https://ror.org/02jfsdq79","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108517"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Peter Webb","raw_affiliation_strings":["Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States","institution_ids":["https://openalex.org/I4210108517"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5114165009","display_name":"Robert R. Webb","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108517","display_name":"Amplyx Pharmaceuticals (United States)","ror":"https://ror.org/02jfsdq79","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108517"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Robert R. Webb","raw_affiliation_strings":["Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States","institution_ids":["https://openalex.org/I4210108517"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5067256770","display_name":"Mitchell W. Mutz","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210108517","display_name":"Amplyx Pharmaceuticals (United States)","ror":"https://ror.org/02jfsdq79","country_code":"US","type":"company","lineage":["https://openalex.org/I4210108517"]}],"countries":["US"],"is_corresponding":true,"raw_author_name":"Mitchell Mutz","raw_affiliation_strings":["Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States. Electronic address: mutz.mitchell@gene.com"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Amplyx Pharmaceuticals, 3210 Merryfield Row, San Diego, CA 92121, United States. Electronic address: mutz.mitchell@gene.com","institution_ids":["https://openalex.org/I4210108517"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":["https://openalex.org/A5028653846","https://openalex.org/A5067256770"],"corresponding_institution_ids":["https://openalex.org/I4210108517"],"apc_list":{"value":3880,"currency":"USD","value_usd":3880},"apc_paid":null,"fwci":2.9401,"has_fulltext":false,"cited_by_count":28,"citation_normalized_percentile":{"value":0.90675722,"is_in_top_1_percent":false,"is_in_top_10_percent":true},"cited_by_percentile_year":{"min":87,"max":98},"biblio":{"volume":"27","issue":"11","first_page":"2465","last_page":"2471"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10150","display_name":"Antifungal resistance and susceptibility","score":0.7099999785423279,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10150","display_name":"Antifungal resistance and susceptibility","score":0.7099999785423279,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12620","display_name":"Signaling Pathways in Disease","score":0.18569999933242798,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10252","display_name":"Microbial Natural Products and Biosynthesis","score":0.03799999877810478,"subfield":{"id":"https://openalex.org/subfields/2402","display_name":"Applied Microbiology and Biotechnology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/calcineurin-inhibition","display_name":"calcineurin inhibition","score":0.8640000224113464},{"id":"https://openalex.org/keywords/antifungal-agents","display_name":"antifungal agents","score":0.9300000071525574},{"id":"https://openalex.org/keywords/aspergillus-fumigatus","display_name":"Aspergillus fumigatus","score":0.9369999766349792},{"id":"https://openalex.org/keywords/immunosuppression","display_name":"immunosuppression","score":0.7609999775886536},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8489999771118164},{"id":"https://openalex.org/keywords/oral-bioavailability","display_name":"oral bioavailability","score":0.6869999766349792},{"id":"https://openalex.org/keywords/antifungal-drug-development","display_name":"antifungal drug development","score":0.5350000262260437}],"concepts":[{"id":"https://openalex.org/C128057223","wikidata":"https://www.wikidata.org/wiki/Q420566","display_name":"Calcineurin","level":3,"score":0.955676794052124},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.7690092325210571},{"id":"https://openalex.org/C2779548794","wikidata":"https://www.wikidata.org/wiki/Q578726","display_name":"Antifungal","level":2,"score":0.6569141149520874},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6077497601509094},{"id":"https://openalex.org/C2776885963","wikidata":"https://www.wikidata.org/wiki/Q245204","display_name":"Antagonist","level":3,"score":0.5878950357437134},{"id":"https://openalex.org/C207001950","wikidata":"https://www.wikidata.org/wiki/Q141124","display_name":"In vivo","level":2,"score":0.43412530422210693},{"id":"https://openalex.org/C89423630","wikidata":"https://www.wikidata.org/wiki/Q7193","display_name":"Microbiology","level":1,"score":0.24209433794021606},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.2246992588043213},{"id":"https://openalex.org/C2911091166","wikidata":"https://www.wikidata.org/wiki/Q106419912","display_name":"Transplantation","level":2,"score":0.11738947033882141},{"id":"https://openalex.org/C86803240","wikidata":"https://www.wikidata.org/wiki/Q420","display_name":"Biology","level":0,"score":0.10355207324028015},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.08511051535606384},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.08369681239128113},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.0786692202091217},{"id":"https://openalex.org/C150903083","wikidata":"https://www.wikidata.org/wiki/Q7108","display_name":"Biotechnology","level":1,"score":0.0}],"mesh":[{"descriptor_ui":"D000818","descriptor_name":"Animals","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000935","descriptor_name":"Antifungal Agents","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D000935","descriptor_name":"Antifungal Agents","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D000935","descriptor_name":"Antifungal Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D000935","descriptor_name":"Antifungal Agents","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D001232","descriptor_name":"Aspergillus fumigatus","qualifier_ui":"Q000187","qualifier_name":"drug effects","is_major_topic":false},{"descriptor_ui":"D002522","descriptor_name":"Chlorocebus aethiops","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007376","descriptor_name":"Interleukin-2","qualifier_ui":"Q000378","qualifier_name":"metabolism","is_major_topic":false},{"descriptor_ui":"D014709","descriptor_name":"Vero Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D016559","descriptor_name":"Tacrolimus","qualifier_ui":"Q000031","qualifier_name":"analogs & derivatives","is_major_topic":true},{"descriptor_ui":"D016559","descriptor_name":"Tacrolimus","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D016559","descriptor_name":"Tacrolimus","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D016559","descriptor_name":"Tacrolimus","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D016559","descriptor_name":"Tacrolimus","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false},{"descriptor_ui":"D019169","descriptor_name":"Jurkat Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D022061","descriptor_name":"Tacrolimus Binding Protein 1A","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":false},{"descriptor_ui":"D056945","descriptor_name":"Hep G2 Cells","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D065095","descriptor_name":"Calcineurin Inhibitors","qualifier_ui":"Q000138","qualifier_name":"chemical synthesis","is_major_topic":false},{"descriptor_ui":"D065095","descriptor_name":"Calcineurin Inhibitors","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D065095","descriptor_name":"Calcineurin Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":true},{"descriptor_ui":"D065095","descriptor_name":"Calcineurin Inhibitors","qualifier_ui":"Q000633","qualifier_name":"toxicity","is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.1016/j.bmcl.2017.04.004","doi":"https://doi.org/10.1016/j.bmcl.2017.04.004","is_oa":false,"landing_page_url":"https://doi.org/10.1016/j.bmcl.2017.04.004","pdf_url":null,"source":{"id":"https://openalex.org/S30970080","display_name":"Bioorganic & Medicinal Chemistry Letters","issn_l":"0960-894X","issn":["0960-894X","1464-3405"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-b","jufo-1","ki-jl-1","medline","norway-1","poland-70","russia-white-list-2","vabb-shw"],"host_organization":"https://openalex.org/P4310320990","host_organization_name":"Elsevier BV","host_organization_lineage":["https://openalex.org/P4310320990"],"host_organization_lineage_names":["Elsevier BV"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & Medicinal Chemistry Letters","raw_type":"journal-article"},{"id":"pmid:28412204","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/28412204","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Bioorganic & medicinal chemistry letters","raw_type":"Journal Article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.9763000011444092}],"study_designs":[],"awards":[{"id":"https://openalex.org/G7891469607","display_name":"Developing a New Therapeutic for the Treatment of Invasive Aspergillosis","funder_award_id":"R44AI106235","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"}],"funders":[{"id":"https://openalex.org/F4320332161","display_name":"National Institutes of Health","ror":"https://ror.org/01cwqze88"},{"id":"https://openalex.org/F4320337355","display_name":"National Institute of Allergy and Infectious Diseases","ror":"https://ror.org/043z4tv69"}],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":31,"referenced_works":["https://openalex.org/W1601157315","https://openalex.org/W1700179117","https://openalex.org/W1819962733","https://openalex.org/W1984754431","https://openalex.org/W1992992109","https://openalex.org/W2004899082","https://openalex.org/W2012067476","https://openalex.org/W2013827595","https://openalex.org/W2014550436","https://openalex.org/W2014787563","https://openalex.org/W2018105404","https://openalex.org/W2026181894","https://openalex.org/W2030425134","https://openalex.org/W2030974772","https://openalex.org/W2035493973","https://openalex.org/W2051542700","https://openalex.org/W2053132428","https://openalex.org/W2080747866","https://openalex.org/W2081581252","https://openalex.org/W2084799310","https://openalex.org/W2092784473","https://openalex.org/W2101274136","https://openalex.org/W2117747228","https://openalex.org/W2122653633","https://openalex.org/W2135732933","https://openalex.org/W2149922169","https://openalex.org/W2152899800","https://openalex.org/W2162294247","https://openalex.org/W2165289393","https://openalex.org/W2169523708","https://openalex.org/W4256074825"],"related_works":["https://openalex.org/W3216223761","https://openalex.org/W4281289403","https://openalex.org/W4386944181","https://openalex.org/W2962777693","https://openalex.org/W2973294764","https://openalex.org/W4405940725","https://openalex.org/W2165289393","https://openalex.org/W2022227140","https://openalex.org/W2467089962","https://openalex.org/W4308347489"],"abstract_inverted_index":null,"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":4},{"year":2023,"cited_by_count":1},{"year":2022,"cited_by_count":5},{"year":2021,"cited_by_count":1},{"year":2020,"cited_by_count":4},{"year":2019,"cited_by_count":4},{"year":2018,"cited_by_count":4},{"year":2017,"cited_by_count":1}],"updated_date":"2026-11-07T11:25:07.637180","created_date":"2017-04-14T00:00:00"}